CanadaBis CapitalTSXV:CANB Gross Margin % is 47.38% as of Oct. 2025, which is 4% above its 10-year median of 45.72. The stock has 6 warning signs investors should review. Among 936 Drug Manufacturers companies, CanadaBis Capital ranks worse than 56.52% on this metric.
The historical rank and industry rank for CanadaBis Capital's Gross Margin % or its related term are showing as below:
TSXV:CANB'
s Gross Margin % Range Over the Past 10 Years
Min: 26.12 Med: 45.72 Max: 53.03
Current: 44.63
During the past 10 years, the highestGross Margin % of CanadaBis Capital was 53.03%. The lowest was 26.12%. And the median was 45.72%.
TSXV:CANB's Gross Margin % is ranked worse than 56.52% of 936
companies
in the Drug Manufacturers industry
Industry Median: 48.5
vs TSXV:CANB: 44.63
CanadaBis Capital had a gross margin of 47.38% for the quarter that ended in Oct. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for CanadaBis Capital was 10.70% per year.
CanadaBis Capital (TSXV:CANB) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CanadaBis Capital had a gross margin of 47.38% for the quarter that ended in Oct. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CanadaBis Capital Gross Margin % Related Terms
CanadaBis Capital Gross Margin % Historical Data
* Premium members only.
The historical data trend for CanadaBis Capital's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:CANB vs NPHC, BSPK, CPMD: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanadaBis Capital's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanadaBis Capital Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanadaBis Capital's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CanadaBis Capital's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CanadaBis Capital (TSXV:CANB) has a Gross Margin % of 47.38% as of Oct. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on CanadaBis Capital and its competitors. This is near median its historical median of 45.72. Over the past decade, CanadaBis Capital's Gross Margin % has ranged from 26.12 to 53.03. According to the industry distribution chart, CanadaBis Capital ranks #529 out of 936 companies in the Drug Manufacturers industry, placing it in the top 56.5%.
Is CanadaBis Capital's Gross Margin % too high?
CanadaBis Capital's current Gross Margin % of 47.38% is near median its 10-year median of 45.72. Over the past 10 years, this metric has ranged from a low of 26.12 to a high of 53.03. The Drug Manufacturers industry median Gross Margin % is 48.50. CanadaBis Capital's value of 47.38% is 2.3% below this industry median. Based on the distribution chart, CanadaBis Capital ranks #529 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does CanadaBis Capital's Gross Margin % compare to NPHC and BSPK?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #529 out of 936 companies for Gross Margin %. This places CanadaBis Capital in the lower half of its industry. The industry median Gross Margin % is 48.50. CanadaBis Capital's value of 47.38% is 2.3% below this benchmark. Historically, CanadaBis Capital's own Gross Margin % has ranged from 26.12 to 53.03 over the past decade. While the company's 10-year median is 45.72 vs. the industry median of 48.50, CanadaBis Capital has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanadaBis Capital's current Gross Margin % of 47.38% is 2.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CanadaBis Capital and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanadaBis Capital's current Gross Margin % is 47.38%, which is near median its own 10-year median of 45.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (TSXV:CANB) has a current Gross Margin % of 47.38%. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current Gross Margin % is 47.38%, which is near median its 10-year median of 45.72 and 2.3% below the Drug Manufacturers industry median of 48.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CanadaBis Capital (TSXV:CANB), the current Gross Margin % is 47.38% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:CANB has been successfully added to your 